Evidence map›Paper›PMID 32734627›Full record

Trial reportClinical and experimental immunology2020

Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis.

S C Sasson, J J Zaunders, K Nahar, C M L Munier, B P Fairfax, A Olsson-Brown, C Jolly, S A Read, G Ahlenstiel, U Palendira and 10 more

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and experimental immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Personalizing Oncolytic Immunovirotherapy Approaches.Molecular diagnosis & therapy · 2024
    Article
  9. Review
  10. Article
  11. Article
  12. Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management.International journal of molecular sciences · 2023
    Review
  13. Review
  14. Article
  15. Review
  16. Interferon-Gamma-Producing CD8Gastroenterology · 2021
    Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 9 institutions in 3 countries.

S C SassonTranslational Gastroenterology Unit and Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0002-5329-9072
J J ZaundersCentre for Applied Medical Research, St Vincent's Hospital, Sydney, Australia.
K NaharMelanoma Institute Australia and The University of Sydney, Sydney, Australia.
C M L MunierThe Kirby Institute, University of New South Wales, Sydney, Australia.
B P FairfaxDepartment of Oncology, Churchill Hospital, Oxford, UK.
A Olsson-BrownThe Clatterbridge Cancer Centre NHS Foundation Trust and Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
C JollyThe Clatterbridge Cancer Centre NHS Foundation Trust and Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
S A ReadWestmead Institute of Medical Research, Sydney, Australia.
G AhlenstielWestmead Institute of Medical Research, Sydney, Australia.
U PalendiraDiscipline of Infectious Diseases and Immunology, The University of Sydney, Sydney, Australia.
R A ScolyerMelanoma Institute Australia and The University of Sydney, Sydney, Australia.
M S CarlinoMelanoma Institute Australia and The University of Sydney, Sydney, Australia.
M J PayneDepartment of Oncology, Churchill Hospital, Oxford, UK.
V T F CheungTranslational Gastroenterology Unit and Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
T GuptaTranslational Gastroenterology Unit and Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
P KlenermanTranslational Gastroenterology Unit and Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
G V LongMelanoma Institute Australia and The University of Sydney, Sydney, Australia.
O Brain *Translational Gastroenterology Unit and Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
A M Menzies *Melanoma Institute Australia and The University of Sydney, Sydney, Australia.
A D Kelleher *Centre for Applied Medical Research, St Vincent's Hospital, Sydney, Australia.
The University of Sydney · AUUniversity of Oxford · GBDongseo University · KRChurchill Hospital · GBUniversity of Liverpool · GBBlacktown & Mount Druitt Hospital · AUSt Vincent's Hospital Sydney · AUUNSW Sydney · AUWestmead Institute · AU

Funding

Medical Research Council MR/N025989/1Wellcome Trust 109965/Z/15/ZWellcome Trust 201488/Z/16/Z
6 · The paper itself

Abstract

The aim of this study was to investigate the pathogenesis of combination ipilimumab and nivolumab-associated colitis (IN-COL) by measuring gut-derived and peripheral blood mononuclear cell (GMNC; PBMC) profiles. We studied GMNC and PBMC from patients with IN-COL, IN-treated with no adverse-events (IN-NAE), ulcerative colitis (UC) and healthy volunteers using flow cytometry. In the gastrointestinal-derived cells we found high levels of activated CD8

Indexed as

CD8-Positive T-LymphocytesColitisIntestinal MucosaMucosal-Associated Invariant T CellsT-Lymphocytes, RegulatoryAdultAgedFemaleFlow CytometryHumansIpilimumabMaleMiddle AgedNivolumabIpilimumabNivolumabcheckpoint inhibitorcolitisipilimumabMAIT cellsnivolumab

Identifiers

PMID32734627
PMCPMC7670140
OpenAlexW3046909302

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.